株式会社フェニックスバイオ

論文一覧

N6-methyladenosine Modification of Hepatitis B Virus RNA in the Coding Region of HBx

Murata, T. Iwahori, S. Okuno, Y. Nishitsuji, H. Yanagi, Y. Watashi, K. Wakita, T. Kimura, H. Shimotohno, K.
Int J Mol Sci. 2023 Jan 23;24(3):2265. doi: 10.3390/ijms24032265.

READ MORE(PUB MED)

Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S
Toxicol Appl Pharmacol. 2023 Apr 15;465:116439. doi: 10.1016/j.taap.2023.116439. Epub 2023 Feb 27.

READ MORE(PUB MED)

A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

READ MORE(PUB MED)

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

READ MORE(PUB MED)

Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.

READ MORE(PUB MED)

Establishment of hyperoxic cell culture system for predicting drug-induced liver injury: reducing accumulated lipids in hepatocytes derived from chimeric mice with humanized liver

Ohtsuki, Y. Sanoh, S. Yamao, M. Kojima, Y. Kotake, Y. Tateno, C.
J Toxicol Sci. 2023;48(2):99-108. doi: 10.2131/jts.48.99.

READ MORE(PUB MED)

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

READ MORE(PUB MED)

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

READ MORE(PUB MED)

Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases

Yarnall, M. T. N. Ioannidi, E. I. Schmitt-Ulms, C. Krajeski, R. N. Lim, J. Villiger, L. Zhou, W. Jiang, K. Garushyants, S. K. Roberts, N. Zhang, L. Vakulskas, C. A. Walker, J. A., 2nd. Kadina, A. P. Zepeda, A. E. Holden, K. Ma, H. Xie, J. Gao, G. Foquet, L. Bial, G. Donnelly, S. K. Miyata, Y. Radiloff, D. R. Henderson, J. M. Ujita, A. Abudayyeh, O. O. Gootenberg, J. S.
Nat Biotechnol. 2022 Nov 24. doi: 10.1038/s41587-022-01527-4.

READ MORE(PUB MED)

Discovery of a first-in-class orally available HBV cccDNA inhibitor

Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

READ MORE(PUB MED)

Consideration of Commercially Available Hepatocytes as Cell Sources for Liver-Microphysiological Systems by Comparing Liver Characteristics

Horiuchi, S. Kuroda, Y. Komizu, Y. Ishida, S.
Pharmaceutics. 2022 Dec 24;15(1):55. doi: 10.3390/pharmaceutics15010055.

READ MORE(PUB MED)

Long-term cell fate and functional maintenance of human hepatocyte through stepwise culture configuration

Sugahara, G. Ishida, Y. Lee, J. J. Li, M. Tanaka, Y. Eoh, H. Higuchi, Y. Saito, T.
FASEB J. 2023 Feb;37(2):e22750. doi: 10.1096/fj.202201292RR.

READ MORE(PUB MED)

A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system

Uchida, T. Yuji, T. Imamura, M. Abe-Chayama, H. Makokha, G. N. Hayes, C. N. Aikata, H. Hamamura, S. Ishida, Y. Tateno, C. Shirouzu, T. Kawai, S. Tanaka, Y. Ohdan, H. Okada, S. Chayama, K.
J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793. https://www.ncbi.nlm.nih.gov/pubmed/36575861

READ MORE(PUB MED)

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
Comparative Medicine 2022, 72(6): 355-363.

READ MORE(PUB MED)

Pegylated interferon therapy-related microRNA-6126 downregulates sodium taurocholate cotransporting polypeptide expression in hepatocytes

Fujita, K. Nishitsuji, H. Iwama, H. Tadokoro, T. Morishita, A. Mimura, S. Ono, M. Himoto, T. Shimotohno, K. Masaki, T.
Gene. 2022 Nov 24;853:147068. doi: 10.1016/j.gene.2022.147068.

READ MORE(PUB MED)

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

READ MORE(PUB MED)

Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2

Nakanishi, A. Okumura, H. Hashita, T. Yamashita, A. Nishimura, Y. Watanabe, C. Kamimura, S. Hayashi, S. Murakami, S. Ito, K. Iwao, T. Ikeda, A. Hirose, T. Sunazuka, T. Tanaka, Y. Matsunaga, T.
Viruses. 2022 Nov 8;14(11):2468. doi: 10.3390/v14112468.

READ MORE(PUB MED)

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

READ MORE(PUB MED)

コラーゲンビトリゲルを用いた新規肝細胞培養系における薬物動態研究

渡　隆爾
関東化学発行誌

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Sakai, K. Sugano-Nakamura, N. Mihara, E. Rojas-Chaverra, N. M. Watanabe, S. Sato, H. Imamura, R. Voon, D. C. Sakai, I. Yamasaki, C. Tateno, C. Shibata, M. Suga, H. Takagi, J. Matsumoto, K.
Nat Biomed Eng. 2022 Nov 7. doi: 10.1038/s41551-022-00955-6.

READ MORE(PUB MED)